Saliva test diagnoses endometriosis in days, not years

Two new noninvasive tools are poised to reshape how endometriosis is diagnosed in the U.K., cutting the typical wait from years to just days. Approved for NHS use while further data are collected, these tests promise faster answers for people who have often endured long diagnostic journeys and chronic pain without a clear cause.

Clinicians and patients alike are calling the developments transformative: one is a saliva-based assay that flags biological markers linked to endometriosis, and the other is a short, sensor-based scan that measures gut electrical activity. Both are being rolled out with NHS funding to help clinicians act sooner and reduce reliance on surgical diagnosis.

What the two new tests do and how they differ

The NHS guidance now supports two diagnostic options that avoid immediate surgery: Endotest, which uses a saliva sample analyzed for microRNA signatures associated with endometriosis, and EndoSure, a 45-minute bedside test that reads electrical signals across the abdomen after a period of fasting. Each test offers a less invasive route to identify likely cases much earlier than traditional methods.

Quick comparison

• Endotest (saliva): Sample sent to a lab for molecular analysis; identifies microRNA patterns that correlate with endometriosis.
• EndoSure (sensor scan): Conducted in clinic; uses sensor pads on the abdomen to measure gut electrical activity; delivers results in about 45 minutes.

Why earlier diagnosis changes lives

Endometriosis affects roughly one in ten people of reproductive age, and until now a definitive diagnosis has commonly required laparoscopy — a minor surgical procedure performed under general anesthesia. That approach, while accurate, has contributed to long delays: many patients wait years, often more than a decade, before receiving a formal diagnosis.

Reducing time to diagnosis is critical because earlier identification enables timely treatment, eases prolonged pain, and can prevent disease progression. Clinicians say quicker, noninvasive testing will help patients start appropriate therapies sooner and relieve pressure on operating theaters reserved for those who truly need surgery.

Real people, real relief: patients share their experiences

Stories from patients who have tried the new tests underline the human impact. One young Pilates instructor in Glasgow experienced symptoms for years and was repeatedly told her pain was intestinal. A noninvasive test finally produced tangible evidence she could bring to her doctor, which led to treatment and a dramatic improvement in daily life.

Another teenager, whose mother is a physician, struggled with severe pelvic pain from age 13. After multiple inconclusive visits, a noninvasive test gave the family the clinical proof needed to secure referrals and ultimately confirm widespread endometriosis, enabling surgery and symptom relief.

A third patient recounted nearly a decade of debilitating periods before receiving surgical treatment; she believes earlier access to noninvasive testing would have prevented progression and spared years of pain.

What happens during each test — step by step

1. Endotest: The patient provides a saliva sample, which is shipped to a laboratory. Technicians analyze microRNA patterns and report whether results are consistent with endometriosis.
2. EndoSure: The patient fasts for a prescribed interval, then rests while sensor pads are placed on the abdomen. The device records electrical signals for roughly 45 minutes and produces an on-site result.

Both tests are noninvasive, require little preparation, and remove the immediate need for a diagnostic laparoscopy unless surgical evaluation is clinically indicated. For many patients, this means a faster path to starting medication, pain management, or referral for surgical treatment when necessary.

Clinical reaction and system-wide benefits

Experts in gynecology and health policy have welcomed the NHS decision. One specialist described the technology as a “game-changer”, noting that earlier diagnosis not only improves individual outcomes but also helps streamline clinic lists and surgical waiting lists by identifying who genuinely needs operative assessment.

Health leaders emphasize that the tests are being supported while additional real-world performance data are collected. If ongoing evaluation confirms accuracy and utility across diverse patient groups, these methods could become standard first-line options for suspected endometriosis.

Signs to look for and why you should seek testing

Endometriosis can present in a variety of ways. Common symptoms include:

• Intense or prolonged menstrual bleeding
• Chronic pelvic pain or severe cramps
• Pain during bowel movements or urination
• Painful intercourse
• Fatigue and reduced quality of life
• Difficulty becoming pregnant

If these symptoms are affecting daily life, asking a primary care provider about noninvasive testing options may lead to faster diagnosis and earlier treatment planning. With the NHS funding these new tools while evidence is gathered, clinicians have more options to investigate symptoms without immediately turning to surgery.

You might also like:

• Cancer breath test hailed as most significant step toward lifesaving breakthrough in 50 years
• NHS women’s health crisis puts patient care at risk
• Stroke rehabilitation: tongue stimulation device outperforms 4 years of therapy in 6 months
• Cancer vaccine reduces melanoma risk 49% after five years
• Alpha-gal syndrome: possible first death linked to tick-induced meat allergy

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.